Neurofibromatosis (nonmalignant)
ICD-10 Q85.0 is a billable code used to indicate a diagnosis of neurofibromatosis (nonmalignant).
Neurofibromatosis (NF) is a genetic disorder characterized by the development of multiple benign tumors called neurofibromas, which arise from the peripheral nervous system. It is classified into two main types: NF1 and NF2, with NF1 being the most common. NF1 is associated with café-au-lait spots, freckling in the axillary or groin regions, and Lisch nodules (iris hamartomas). Patients may also experience learning disabilities and other neurological complications. The condition is caused by mutations in the NF1 gene located on chromosome 17. Neurofibromatosis is considered a congenital malformation due to its genetic basis and early onset, often presenting in childhood. While the tumors are nonmalignant, they can lead to significant morbidity due to their location and size. Management typically involves regular monitoring and surgical intervention when necessary. Accurate coding of neurofibromatosis requires careful documentation of the clinical features and any associated complications.
Pediatric documentation should include growth and developmental assessments, family history, and any neurological evaluations.
Common scenarios include routine monitoring of neurofibromas, management of learning disabilities, and referrals for surgical evaluation.
Considerations include the age of onset, family history of neurofibromatosis, and the presence of other congenital anomalies.
Genetic documentation should include results of genetic testing, family pedigree, and counseling notes regarding inheritance patterns.
Genetic counseling for families with a history of neurofibromatosis and discussions about the implications of genetic testing.
Considerations include the need for genetic testing to confirm diagnosis and assess risk for family members.
Used for routine follow-up visits for patients with neurofibromatosis.
Document history, examination findings, and any management plans.
Pediatricians should focus on developmental assessments during visits.
NF1 is characterized by skin lesions and neurological complications, while NF2 primarily involves tumors affecting hearing. Accurate coding requires distinguishing between the two types based on clinical findings.
